Nasivin (Oxymetazoline Hydrochloride)

Oxymetazoline hydrochloride is a selective alpha‑1 and partial alpha‑2 adrenergic agonist. By activating these receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and fluid accumulation, leading to rapid decongestion of the nasal passages.

The appropriate dose of Nasivin is determined by a healthcare professional based on the individual’s age, condition, and response to therapy. Typically, one or two sprays per nostril are used, but the prescriber’s instructions should always be followed.

Safety data for oxymetazoline during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Nasivin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nasivin’s active ingredient, oxymetazoline, provides rapid and potent vasoconstriction, often lasting longer than phenylephrine‑based sprays. However, like all topical decongestants, it should not be used for more than three days to avoid rebound congestion, a limitation shared with other agents in the class.

Store Nasivin at room temperature, ideally below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Nasivin is administered as a nasal spray. The user tilts the head slightly forward, inserts the tip into a nostril, and presses the pump to deliver the recommended number of sprays. The same procedure is repeated for the other nostril if required.

Serious risks, though rare, include significant elevation of blood pressure, cardiac arrhythmias, severe nasal ulceration or septal perforation, and allergic reactions such as rash or swelling. If any of these occur, discontinue use and seek medical attention promptly.

Nasivin should be avoided by individuals with known hypersensitivity to oxymetazoline or any formulation components, patients with severe hypertension, those taking MAO inhibitors, and children under six years of age unless directed by a physician.